Introduction
Cerebrotendinous xanthomatosis is a lipid storage disease characterized by diarrhea, cataract, tendon xanthoma and neurological dysfunction. The onset of these features follows a chronological order. CYP27A1 is the only gene in which mutations are known to cause Cerebrotendinous xanthomatosis. CYP27A1 gene is located in chromosome 2q33 and contains nine exons. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This mitochondrial protein oxidizes cholesterol intermediates as part of the bile synthesis pathway. Since the conversion of cholesterol to bile acids is the major route for removing cholesterol from the body, this protein is important for overall cholesterol homeostasis. Early diagnosis by biochemical testing or molecular genetic testing if the two disease-causing mutations in the family are known allows for early treatment that may prevent or limit disease manifestations. Cerebrotendinous xanthomatosis is inherited in an autosomal recessive manner. To date around 90% of cases of Cerebrotendinous xanthomatosis have been ascribed to point mutations and another 8% to deletions or duplications [1] .
Material and methods
Two Indian families (family 1 and family 2) with a clinical diagnosis of Cerebrotendinous xanthomatosis were recruited for CYP27A1 gene analysis after obtaining informed consent. The clinical, laboratory and radiological characteristics are summarized in Table 1 .
The study was funded by Christian Medical College, Vellore fluid research grant (IRB No. 8491/9-10-13). The study was approved by the Institutional Review Board and the Ethics Committee and 5 ml of blood was collected aseptically from the affected patients, parents, (father of affected family 1 was unavailable) and unaffected siblings. DNA was extracted with QIAamp DNA Minikit from Qiagen as per standard protocol. DNA purity was checked in a Nanodrop instrument. PCR of all exons and intron-exon boundaries was done using a published protocol [2] . PCR products were visualized by electrophoresis in 2% agarose gel. PCR Molecular Genetics and Metabolism Reports 3 (2015) 33-35 products were purified using Exosap kit from Qiagen. PCR products were sequenced by Sanger sequencing in ABI 3500 genetic analyzer. Sequences were analyzed in Ensemble database and pathogenic mutations were checked in Human Genome Mutation Database (public version) for previous reports on 02.09.2014.
Results
The genotyping results are summarized in Table 2 . Two affected individuals from the first family had a homozygous c.526delG mutation and the mother is a heterozygote - Fig. 1 . This is a known pathogenic mutation which leads to frame shift. The single affected individual from the second family had a homozygous c.446 + 1G-A mutation. This is also a known splice donor site mutation. Parents are heterozygotes - Fig. 2 .
Discussion
We describe two different mutations in the CTX patients belonging to two different regions of India. The first familial case from Eastern India has homozygous c.526delG.mutation, the affected sister is homozygous while the mother who is unaffected is heterozygous for this known mutation. The father was unavailable for testing and is presumed to be a carrier. The second case and the first one to be reported from South India have homozygous c.446 + 1G-A mutation which is already reported in heterozygous state in a Spanish patient [3] . The parents are heterozygous for the mutation. Previously our laboratory has reported the first Indian case with the same homozygous c.526delG mutation also from Eastern India [4] . Another report from the Northern part of the Country described a patient with compound heterozygous (c. 1151C N T p. P384L and c. 2T N C p.M1T) [5] . Patients from all three regions have separate mutations. However to date two unrelated Eastern Indian families have the same homozygous c.526delG mutation.
The only documented report of the same mutation was from the Netherlands in a Surinamese patient [6] . The pathogenic mutations in Cerebrotendinous xanthomatosis are usually restricted to specific populations except for R362C mutation which has been reported from the Netherlands and the USA (Black) [7] . The present reported mutation is the second of its kind to be reported from two different populations.
As human trading between Eastern India and Surinam was prevalent in the ninetieth century this mutation might represent a common founder mutation [8] .
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